ReviewClinical and translational radiation oncology2026
Magnetic resonance imaging findings after stereotactic body radiation therapy for hepatocellular carcinoma - a scoping literature review.
Review in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiotherapy (SBRT) is an established locoregional treatment option for hepatocellular carcinoma (HCC). However, post-treatment imaging remains challenging because tumor response and focal liver reaction (FLR), defined as radiation-related alterations of the adjacent liver parenchyma, may both evolve gradually and mimic viable or recurrent tumor. We conducted a scoping review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). PubMed, Embase, and manual reference screening were used to identify studies published between January 2012 and February 2025 that evaluated MRI findings after SBRT for HCC. Studies were eligible if they reported MRI-based post-treatment outcomes after stereotactic, image-guided, highly conformal external-beam radiotherapy delivered in a limited number of fractions with ablative intent. Studies evaluating non-SBRT regimens, non-MRI imaging modalities, theoretical modeling approaches, reviews, and case reports were excluded. Eight studies met the inclusion criteria. Overall, MRI findings after SBRT demonstrated a delayed and time-dependent pattern rather than immediate tumor regression. In responding lesions, arterial phase hyperenhancement (APHE) and washout commonly decreased over time or evolved toward delayed enhancement or non-enhancement. T2-weighted and diffusion-weighted imaging (DWI) signal intensity tended to decline, whereas apparent diffusion coefficient (ADC) values increased. FLR was frequently observed and included perilesional enhancement, hepatobiliary phase hypointensity, capsular retraction, and dose-related parenchymal changes on gadoxetic acid-enhanced MRI. Response assessment after SBRT should therefore rely on serial multiparametric MRI rather than early arterial enhancement alone. Persistent enhancement shortly after treatment should not automatically be interpreted as treatment failure, and FLR remains an important source of diagnostic uncertainty. Prospective studies are needed to standardize MRI protocols, follow-up intervals, and response assessment criteria in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.